Hernia graft study halted early – what we know

NCT ID NCT04294446

Terminated Disease control Sponsor: Cook Biotech Incorporated Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the Biodesign Hernia Graft, a device made from pig intestinal tissue, used to strengthen the abdominal wall during ventral hernia repair. It enrolled 74 adults needing surgery for a primary or recurrent hernia. The goal was to track hernia recurrence and side effects like infection over two years. However, the study was terminated early, so the full picture is limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Biodesign Hernia Graft (a device made from pig intestinal tissue to reinforce hernia repair)
What this could lead to: If successful, this could confirm the graft is safe and effective for routine use in ventral hernia repair.
What could go wrong: The study was terminated early, so results may be incomplete. Hernia recurrence and complications like infection remain possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VENTRAL HERNIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hernia, Ventral

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VENTRAL HERNIA

Contacts and locations

Locations

Queen Elizabeth II Hospital

Halifax, Nova Scotia, B3H 2Y9, Canada
St. Paul's Hospital

Vancouver, British Columbia, V6Z 1Y6, Canada
Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.